期刊文献+

一种新型口服GnRH拮抗剂——Elagolix 预览

A New Oral GnR H Antagonist——Elagolix
在线阅读 下载PDF
收藏 分享 导出
摘要 艾伯维(AbbVie)于2017年9月6日向美国食品药品监督管理局(FDA)提交了将Elagolix用于治疗子宫内膜异位症的新药申请,并在1个多月后获得了FDA的优先审评资格。Elagolix是一种口服的促性腺激素释放激素拮抗剂(GnRH_A),对于子宫内膜异位症引起的月经痛和非月经盆腔痛具有很好的疗效。与以往大家所熟知的GnRH激动剂(GnRHa)相比,具有较高的口服生物利用度,避免了注射引起的疼痛感和过敏反应,增加了患者依从性。目前该药物延期通过,涉及补充肝损伤的资料,FDA将于2018年第3季度回复意见,对于不良反应肝损伤的原理尚不清楚。Elagolix有望成为治疗子宫内膜异位症的新型口服GnRH_A,对于后续研究进展将持续关注。 Abb Vie submitted a new drug application for Elagolix to the FDA on September 6, 2017, and received the FDA's priority review in more than a month. Elagolix is an oral gonadotropin-releasing hormone(GnRH) antagonist, has the very good curative effect on endometriosis for menstrual pelvic pain. Compared with and previously known as GnRH agonists,Elagolix has high oral bioavailability, and avoid the pain caused by injection and allergic reaction, and increased patient compliance. Currently, the drug has been delayed to the FDA in the third quarter of 2018 regarding the supplementary data on liver injury. The principle of adverse reactions to liver injury is not clear. Elagolix hopes to be a new oral GnRH antagonist agent in the treatment of endometriosis, and we will continue to pay attention to the follow-up research progress.
作者 王诗惠 张杰 纪英博 张永凯 WANG Shi-hui,ZHANG Jie,JI Ying-bo,ZHANG Yong-kai (Department of Pharmacy,The First Hospital of Jilin University,Changchun 130000,China )
出处 《国际妇产科学杂志》 CAS 2018年第4期327-330,共4页 Foreign Medical Sciences(Obstet Gynecol Fascicle)
关键词 Elagolix 子宫内膜异位症 促性腺素释放激素 Elagolix Endometriosis Gonadotropin-releasing hormone
  • 相关文献

参考文献4

二级参考文献17

  • 1Hayashi A, Tanabe A, Kawabe S, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis [J]. J Ovarian Res, 2012, 5(1): 31. 被引量:1
  • 2Bulletti C, Coccia M E, Battistoni S, et al. Endometriosis and infertility [J]. J Assist Reprod Genet, 2010, 27(8): 441-447. 被引量:1
  • 3Culley L, Law C, Hudson N, et al. The social and psychological impact of endometriosis on women's lives: a critical narrative review [J]. Hum Reprod Update, 2013, 19(6): 625-639. 被引量:1
  • 4Fauser B C, Diedrich K, Bouchard P, et al. Contemporary genetic technologies and female reproduction[J]. Hum Reprod Update, 2011, 17(6): 829-847. 被引量:1
  • 5Ballard K, Lane H, Hudelist G; et al. Can specific pain symptoms help in the diagnosis of endometriosis? A cohort study of women with chronic pelvic pain [J]. Fertil Steril, 2010, 94(1): 20-27. 被引量:1
  • 6Vercellini P, Eskenazi B, Consonni D, et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis [J]. Hum Reprod Update, 2011, 17(2): 159-170. 被引量:1
  • 7Carr B, Dmowski W P, O'Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxy- progesterone acetate for the treatment of endometriosis: effects on bone mineral density [J]. Reprod Sei, 2014, 21(11): 1341-1351. 被引量:1
  • 8Ezzati M, Carr B R. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain [J]. Womens Health (Lond Engl), 2015, 11(1): 19-28. 被引量:1
  • 9Chert C, Wu D, Guo Z, et al. Discovery of sodium R-(+)-4- {2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6- [trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro- 2H-pyrimidin- 1-yl]- 1-phenylethylamino } butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor [J]. J Med Chem, 2008, 51(23): 7478-7485. 被引量:1
  • 10Guo Z Q, Chen Y S, Wu D P, et al. Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists [P]. WO: 2005/007165, 2015-01-27. 被引量:1

共引文献353

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈